John Andrews, MD
Internal Medicine · Santa Monica, CANPI 1447262126
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Globus Medical accounts for 85.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $6,130 and has fallen 95.7% since, to $262 in 2024. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $160.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$6K
- Lilly USA, LLC$147
- Sanofi-aventis U.S. LLC$125
- Novartis$119
- Amgen$102
- GSK$70
- plus $427 from 12 others
What the payments were for
- Consulting fees$3,81956%
- Speaking & faculty fees$1,95029%
- Food & beverage$99115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 2 | $5,769 |
| Lilly USA, LLC | 6 | $147 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Novartis | 5 | $119 |
| Amgen | 5 | $102 |
| GSK | 3 | $70 |
| AstraZeneca | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Medtronic | 1 | $28 |
| Novo Nordisk | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Exact Sciences | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $26 |
| Pfizer | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quartex$5,769
- DISEASE STATE$125
How this compares
$6,760 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $37,525 |
| MounjaroTirzepatide | 34 | $35,580 |
| EliquisApixaban | 34 | $29,070 |
| OzempicSemaglutide | 25 | $26,435 |
| Repatha SureclickEvolocumab | 35 | $23,242 |
| RybelsusSemaglutide | 13 | $12,230 |
| JanuviaSitagliptin Phosphate | 13 | $8,309 |
| GemtesaVibegron | 13 | $7,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,109 |
| SynthroidLevothyroxine Sodium | 48 | $3,293 |
| Fentanyl | 11 | $2,211 |
| Silodosin | 16 | $1,986 |
| Rosuvastatin Calcium | 112 | $1,520 |
| Ezetimibe | 49 | $1,505 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $1,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $28 | $38,66638 claims |
| Lilly USA, LLCMounjaro | $147 | $35,58034 claims |
| PfizerEliquis, Paxlovid | $22 | $30,49951 claims |
| GSKTrelegy Ellipta | $70 | $7,10911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Santa Monica
- Stephen KaniaSanta Monica$555K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.